Denali Therapeutics Inc. (DNLI)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $20.07
- As of
Kresmion compiles this page from DNLI's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Denali Therapeutics Inc. (DNLI): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-03.
See the full DNLI dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for DNLI on one page. Preview it with sample data, then open it live with a free account.
Preview the DNLI dossierActive events for DNLI
- mediumEarnings below estimates
Q3-2026: Missed consensus by 18.0%, EPS $-0.64 vs $-0.5426 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +1041% to DNLI (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +94% to DNLI (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +68% to DNLI (2026Q2)
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +7405% to DNLI (2026Q2)
FREE, NO ACCOUNT
Every event on DNLI, as it fires
You are seeing 5 of 9 events recorded on DNLI since 2026-05-31.
The five above landed across 2 days. The other 4 were recorded on 2 other days. 7 of the 9 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
DNLI positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| MILLENNIUM MANAGEMENT LLC FundCUSIP 24823R105 · 2026Q2 | $29M | 0.02% |
| CITADEL ADVISORS LLC FundCUSIP 24823R105 · 2026Q2 | $1.7M | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, DNLI
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
More data on DNLI
DNLI against its peers
DNLI's return on equity of -50.6% ranks in the 34th percentile of 24 Biotechnology sub-industry peers, fiscal periods ending between 2025-11-30 and 2025-12-31.
| Metric | DNLI | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 126M USD | 6 | 17 |
| Gross margin | n/a | 57.4% | n/a | 7 |
| Operating margin | n/a | -165.7% | n/a | 16 |
| Net margin | n/a | -110.8% | n/a | 16 |
| Return on equity | -50.6% | -29.0% | 34 | 24 |
Peers (24): IDYA, TLX, DYN, NRIX, ELVN, VRDN, BEAM, CELC, ZLAB, ATAI.D, GRTX.D, MBX, VKTX, ACAD, ADMA, IRON, XNCR, XENE, PGEN, TNGX, RXRX, IOVA, CPRX.D, PHVS. Left out: PBLS (no annual filing). Fiscal periods ending between 2025-11-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (DNLI: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in DNLI on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on DNLI in the last 180 days.
Upstream: SEC EDGAR filings for DNLI
Kresmion, "Denali Therapeutics Inc. (DNLI) institutional holdings and SEC filings", data as of 2026-11-06, https://kresmion.com/research/DNLI. Upstream data: SEC EDGAR filings for DNLI.
Link to this data (HTML):
<a href="https://kresmion.com/research/DNLI">Denali Therapeutics Inc. (DNLI) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow DNLI on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to DNLI for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.